Inventiva SA
6IVA
Company Profile
Business description
Inventiva SA is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with unmet medical needs.
Contact
50 rue de Dijon
Daix21121
FRAT: +33 380447500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
77
Stocks News & Analysis
stocks
Long term outlook intact for wide moat income share
Acquisition gains balance traffic headwinds.
stocks
ASX rare earths play looks to expand production
The largest rare-earth producer outside of China acquires competitor to increase production.
stocks
Anthropic’s leaked financials reflect fast growth, but not a $2 trillion valuation
Draft IPO filing shows a company growing faster than its annual results can capture.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,894.60 | 8.90 | -0.10% |
| CAC 40 | 7,819.57 | 45.50 | -0.58% |
| DAX 40 | 25,239.85 | 209.34 | -0.82% |
| Dow JONES (US) | 51,521.28 | 253.38 | 0.49% |
| FTSE 100 | 10,501.87 | 39.82 | -0.38% |
| HKSE | 24,155.44 | 125.12 | -0.52% |
| NASDAQ | 27,599.89 | 122.58 | 0.45% |
| Nikkei 225 | 70,035.71 | 648.27 | -0.92% |
| NZX 50 Index | 13,684.04 | 16.08 | -0.12% |
| S&P 500 | 7,818.93 | 44.98 | 0.58% |
| S&P/ASX 200 | 8,727.70 | 8.00 | -0.09% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |